Tavlesse (fostamatinib)
- Region
- 🇪🇺 EU
- Active substance
- fostamatinib
- Company
- Instituto Grifols S.A.
- Status
- Authorised
- Therapeutic area
- Thrombocytopenia
- EU approval
- Thu 09 Jan 2020
- Application
- EMEA/H/C/005012
- ATC
- B02BX
- Official record
- www.ema.europa.eu
Indication
Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.
Regulatory milestones
No milestones recorded in the last year.
Follow Tavlesse
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.